DADC
CADX

D.A. Davidson & Co’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

D.A. Davidson & Co’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,000
Closed -$6K – 2192
2013
Q3 		$6K Hold
1,000
– – ﹤0.01% 1565
2013
Q2 		$6K Buy
+1,000
New +$6.97K ﹤0.01% 1520

Other funds holding CADX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.A. Davidson & Co's CADX Position: Q4 2013 in Review

D.A. Davidson & Co sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 1,000 shares — an estimated $6K sold.

D.A. Davidson & Co first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $6K in Q3 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

  • D.A. Davidson & Co reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,000 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $6K.
  • D.A. Davidson & Co first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
  • D.A. Davidson & Co's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $6K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on D.A. Davidson & Co's 13F filing for Q4 2013, filed 12 Feb 2014.